A virtual disruptive late clinical-stage novel ophthalmology drug platform

Theialife is aiming to reduce myopic progression in children & build a portfolio of innovative ophthalmic range for vision threatening complications. Bringing the “discovery” back to “drug-discovery” in ophthalmology.

Because every eye deserves sight.  

For the future of every childs vision.

LEAD PRODUCT CANDIDATES

Our late-stage phase 3 drug – 7MX – provides unique therapeutic options for millions of diagnosed but untreated or undertreated myopia in children.

Are you a patient?

Learn more about myopia & how to treat it.

Click here

Meet us at

Theialife is featured on the front cover of the coveted British Journal of Ophthalmology 

To learn more about the groundbreaking benefits of 7-Methyl-Xanthine in the use of Myopia control and treatment in children, The British journal of Ophthalmology published a peer-reviewed article.

August 18, 2022

Read more

Theialife is featured in the International Journal of Ophthalmology

Featured in a second peer-reviewed publication in the International Journal of Ophthalmology. Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review” 

January 31, 2023 

Read more